3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
6
Sarcoma
1
NET
1
Endocrine
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
4
Surgical Procedures, Operative
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
aldesleukin
2
Yoga
2
Temozolomide
2
Surveys and Questionnaires
2
Paclitaxel
2
Imatinib Mesylate
2
Gadolinium DTPA
2
Donepezil
2
Carmustine
2
Bortezomib
2
vatalanib
1
temsirolimus
1
sargramostim
1
olaparib
1
lutetium Lu 177 dotatate
1
gallium Ga 68 dotatate
1
gadobutrol
1
gadobenic acid
1
entinostat
1
carboxyamido-triazole
1
Vorinostat
1
Verteporfin
1
Thalidomide
1
Semaxinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
lutetium Lu 177 dotatate
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled